Iyad Pharma Tech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 2 Months
- Last Filing with ROC 31 Mar 2019
About Iyad Pharma Tech
Iyad Pharma Tech Private Limited (IPTPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 November 2018 (Six years and two months 25 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Machinery And Equipment Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Nadeem Khan and Sajid Khan serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U29100MH2018PTC317688
- Company No.
317688
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Nov 2018
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
What products or services does Iyad Pharma Tech Private Limited offer?
Iyad Pharma Tech Private Limited offers a wide range of products and services, including Pollution Control Devices & Machines, Air Pollution Control Equipment, Filling Machines & Plants, Bottling Plant, Filling Machines, Pharmaceutical Machinery & Equipment, Tablet Making Machines, Capsule Making Machine, Viscous Liquid Filling Machine, Liquid Filling Machine.
Who are the key members and board of directors at Iyad Pharma Tech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nadeem Khan  | Director | 30-Nov-2018 | Current |
| Sajid Khan | Director | 30-Nov-2018 | Current |
Financial Performance of Iyad Pharma Tech.
Iyad Pharma Tech Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Iyad Pharma Tech?
In 2019, Iyad Pharma Tech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Zako Buildsystems Private LimitedNadeem Khan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Iyad Pharma Tech?
Unlock and access historical data on people associated with Iyad Pharma Tech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Iyad Pharma Tech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Iyad Pharma Tech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.